The 2030s may feel like a distant horizon. But when it comes to compounding wealth, the best time to plant the seeds is now.
ASX growth shares that can steadily expand their earnings year after year often deliver outsized rewards for patient investors.
But which shares could do this for an investment portfolio? Let's take a look at three that analysts are tipping to grow strongly in the coming years. They are listed below:
Goodman Group (ASX: GMG)
Goodman Group is one of the world's leading industrial property developers and managers. Its focus on high-quality logistics facilities, warehouses, and data centres has put it at the heart of the global ecommerce boom.
Amazon (NASDAQ: AMZN) and major retailers rely on Goodman's modern logistics infrastructure to meet customer expectations in a world of same-day and next-day delivery.
Looking further ahead, Goodman is now leaning into data centre development, a sector that will only expand as cloud computing and artificial intelligence drive demand for secure, scalable infrastructure. Its combination of property expertise, global reach, and exposure to megatrends makes it a formidable long-term holding.
Bell Potter currently has a buy rating and $40.75 price target on its shares.
NextDC Ltd (ASX: NXT)
Another ASX growth share that could be a top pick is NextDC. It is another ASX-listed powerhouse in digital infrastructure.
The company owns and operates data centres across Australia and is expanding into Asia. Its facilities host the backbone of the digital economy, providing the secure and scalable capacity needed by cloud providers, enterprises, and government organisations.
With artificial intelligence workloads, streaming services, and global cloud adoption accelerating, demand for NextDC's capacity has surged. The company's forward order book sits at record highs, and management continues to invest heavily in new projects to meet future demand.
Macquarie is a big fan and has an outperform rating and $22.30 price target on its shares.
Pro Medicus Ltd (ASX: PME)
A third ASX growth share to hold onto until the 2030s could be Pro Medicus. It is one of Australia's leading healthcare technology companies. Its Visage imaging software is used by hospitals and radiology groups to manage and analyse medical images faster and more efficiently.
In recent years, the company has been winning major contracts with leading US healthcare providers, driving both strong revenue growth and recurring earnings. Pro Medicus' high-margin business model, long-term contracts, and mission-critical products make it a compelling growth story. And with healthcare systems worldwide under pressure to improve efficiency and outcomes, demand for its software should only grow stronger through the 2030s.
Citi is bullish and has a buy rating and $350.00 price target on its shares.
